Q4 Earnings Estimate for CRDF Issued By Noble Financial

Cardiff Oncology, Inc. (NASDAQ:CRDF) – Analysts at Noble Financial issued their Q4 2025 earnings per share estimates for Cardiff Oncology in a research report issued to clients and investors on Monday, January 5th. Noble Financial analyst R. Leboyer forecasts that the company will post earnings of ($0.18) per share for the quarter. Noble Financial currently has a “Outperform” rating and a $12.00 target price on the stock. The consensus estimate for Cardiff Oncology’s current full-year earnings is ($0.99) per share. Noble Financial also issued estimates for Cardiff Oncology’s Q1 2026 earnings at ($0.19) EPS, Q2 2026 earnings at ($0.20) EPS, Q3 2026 earnings at ($0.21) EPS, Q4 2026 earnings at ($0.22) EPS, FY2028 earnings at ($0.92) EPS and FY2029 earnings at ($0.01) EPS.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cardiff Oncology in a research note on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Cardiff Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $11.13.

Cardiff Oncology Stock Performance

Shares of CRDF stock opened at $2.97 on Wednesday. The firm has a fifty day moving average of $2.41 and a 200-day moving average of $2.58. The stock has a market cap of $200.06 million, a price-to-earnings ratio of -3.76 and a beta of 1.40. Cardiff Oncology has a 52-week low of $1.90 and a 52-week high of $4.99.

Cardiff Oncology (NASDAQ:CRDF) last issued its earnings results on Thursday, November 6th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.03. The firm had revenue of $0.12 million during the quarter, compared to analysts’ expectations of $0.12 million. Cardiff Oncology had a negative return on equity of 77.21% and a negative net margin of 10,064.27%.

Institutional Investors Weigh In On Cardiff Oncology

Hedge funds and other institutional investors have recently bought and sold shares of the company. Jeppson Wealth Management LLC bought a new stake in Cardiff Oncology during the third quarter worth $25,000. Brooklyn Investment Group bought a new position in shares of Cardiff Oncology during the 3rd quarter worth approximately $26,000. Baader Bank Aktiengesellschaft acquired a new position in shares of Cardiff Oncology during the 2nd quarter worth approximately $32,000. Belpointe Asset Management LLC acquired a new stake in Cardiff Oncology during the 1st quarter valued at $37,000. Finally, Integrity Alliance LLC. acquired a new stake in Cardiff Oncology during the 2nd quarter valued at $41,000. Institutional investors and hedge funds own 16.29% of the company’s stock.

Key Cardiff Oncology News

Here are the key news stories impacting Cardiff Oncology this week:

• Positive Sentiment: Noble Financial initiated coverage with an Outperform rating and a $12.00 price target (roughly 300%+ upside vs. the recent price), a clear catalyst that can attract buyers and research-driven flows. Noble Financial Begins Coverage on Cardiff Oncology (NASDAQ:CRDF)
• Positive Sentiment: Noble’s long-range forecast includes a FY2030 EPS of $2.30, implying management or the analyst expects successful clinical / commercial progress over the next several years — a bullish structural thesis for growth investors.
• Neutral Sentiment: Noble provided a detailed quarterly cadence of EPS estimates (Q4’25–Q4’26 and FY2025–FY2029), giving investors clearer expectations for near-term results and milestones that will be monitored going forward.
• Negative Sentiment: Near-term estimates remain negative: consensus full‑year EPS is around ($0.99) and Noble projects losses through FY2029 (small loss in FY2029), highlighting that Cardiff is still pre‑profit and reliant on clinical progress or financing; this raises execution and dilution risk for investors.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.